Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells

References

• Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol. 2013;717(1–3):58–66. doi:10.1016/j.ejphar.2013.02.057
   PubMed Web of Science ®Google Scholar
• Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem. 2010;17:786–800. doi:10.2174/092986710790514507
   PubMed Web of Science ®Google Scholar
• Naito S, Hasegawa S, Yokomizo A, et al. Non‐P‐glycoprotein‐mediated atypical multidrug resistance in a human bladder cancer cell line. Jap J Cancer Res. 1995;86:1112–1118. doi:10.1111/j.1349-7006.1995.tb03028.x
   PubMedGoogle Scholar
• Staud F, Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol. 2005;37:720–725. doi:10.1016/j.biocel.2004.11.004
   PubMed Web of Science ®Google Scholar
• Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768–780. doi:10.1016/S0344-0338(96)80099-9
   PubMed Web of Science ®Google Scholar
• Tendulkar S, Dodamani S. Chemoresistance in ovarian cancer: prospects for new drugs. Anticancer Agents Med Chem. 2020. doi:10.2174/1871520620666200908104835
   Web of Science ®Google Scholar
• Ruan T, Liu W, Tao K, Wu C. A review of research progress in multidrug-resistance mechanisms in gastric cancer. Onco Targets Ther. 2020;Volume 13:1797–1807. doi:10.2147/OTT.S239336
   Web of Science ®Google Scholar
• Baji Á, Kiss T, Wölfling J, et al. Multicomponent access to androstano-arylpyrimidines under microwave conditions and evaluation of their anti-cancer activity in vitro. J Steroid Biochem Mol Biol. 2017;172:79–88. doi:10.1016/j.jsbmb.2017.06.001
   PubMed Web of Science ®Google Scholar
• Beusterien K, Grinspan J, Kuchuk I, et al. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist. 2014;19(2):127–134. doi:10.1634/theoncologist.2013-0359
   PubMed Web of Science ®Google Scholar
• Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29(2):93–100. doi:10.1016/j.blre.2014.09.012
   PubMed Web of Science ®Google Scholar
• Kovács D, Szoke K, Igaz N, et al. Silver nanoparticles modulate ABC transporter activity and enhance chemotherapy in multidrug resistant cancer. Nanomedicine. 2016;12:601–610. doi:10.1016/j.nano.2015.10.015
   PubMed Web of Science ®Google Scholar
• Kovács D, Igaz N, Marton A, et al. Core-shell nanoparticles suppress metastasis and modify the tumour-supportive activity of cancer-associated fibroblasts. J Nanobiotechnology. 2020;18. doi:10.1186/s12951-020-0576-x
   PubMed Web of Science ®Google Scholar
• Igaz N, Kovács D, Rázga Z, Kónya Z, Boros IM, Kiricsi M. Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles. Colloids Surf B Biointerfaces. 2016;146:670–677. doi:10.1016/j.colsurfb.2016.07.004
   PubMed Web of Science ®Google Scholar
• Igaz N, Szőke K, Kovács D, et al. Synergistic radiosensitization by gold nanoparticles and the histone deacetylase inhibitor SAHA in 2D and 3D cancer cell cultures. Nanomaterials. 2020;10(1):158. doi:10.3390/nano10010158
   Web of Science ®Google Scholar
• Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921–7924. doi:10.7150/thno.49577
   PubMed Web of Science ®Google Scholar
• Das RP, Gandhi VV, Singh BG, Kunwar A. Passive and active drug targeting: role of nanocarriers in rational design of anticancer formulations. Curr Pharm Des. 2019;25(28):3034–3056. doi:10.2174/1381612825666190830155319
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534. doi:10.1002/adma.201104763
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine: Nanotechnology, Biology and Medicine. 2015;11(2):313–327. doi:10.1016/j.nano.2014.09.014
   PubMed Web of Science ®Google Scholar
• Giri S, Trewyn BG, Lin VSY. Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine. 2007;2(1):99–111. doi:10.2217/17435889.2.1.99
   PubMed Web of Science ®Google Scholar
• Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60:1278–1288. doi:10.1016/j.addr.2008.03.012
   PubMed Web of Science ®Google Scholar
• Lai CY, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc. 2003;125. doi:10.1021/ja028650l
   Web of Science ®Google Scholar
• Bharti C, Gulati N, Nagaich U, Pal A. Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig. 2015;5(3):124. doi:10.4103/2230-973x.160844
   PubMed Web of Science ®Google Scholar
• Barui S, Cauda V. Multimodal decorations of mesoporous silica nanoparticles for improved cancer therapy. Pharmaceutics. 2020;12(6):527. doi:10.3390/pharmaceutics12060527
   PubMed Web of Science ®Google Scholar
• Cai L, Zhu P, Huan F, et al. Toxicity-attenuated mesoporous silica Schiff-base bonded anticancer drug complexes for chemotherapy of drug resistant cancer. Colloids Surf B Biointerfaces. 2021. doi:10.1016/j.colsurfb.2021.111839
   Web of Science ®Google Scholar
• Zhu P, Xu Z, Cai L, Chen J. Porphyrin iron-grafted mesoporous silica composites for drug delivery, dye degradation and colorimetric detection of hydrogen peroxide. Nanoscale Res Lett. 2021;16. doi:10.1186/s11671-021-03501-6
   Web of Science ®Google Scholar
• Iturrioz-Rodríguez N, Correa-Duarte MA, Fanarraga ML. Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles. Int J Nanomedicine. 2019;Volume 14:3389–3401. doi:10.2147/IJN.S198848
   Web of Science ®Google Scholar
• Kars MD, Işeri ÖD, Gündüz U, Ural AU, Arpaci F, Molnár J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res. 2006;26:4559–4568.
   PubMed Web of Science ®Google Scholar
• Gopisetty MK, Adamecz DI, Nagy FI, et al. Androstano-arylpyrimidines: novel small molecule inhibitors of MDR1 for sensitizing multidrug-resistant breast cancer cells. Eur J Pharm Sci. 2021;156:105587. doi:10.1016/j.ejps.2020.105587
   PubMed Web of Science ®Google Scholar
• Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine. 2015;11:1657–1666. doi:10.1016/j.nano.2015.05.011
   PubMed Web of Science ®Google Scholar
• Lei W, Sun C, Jiang T, et al. Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy. Mater Sci Eng C. 2019;105:110103. doi:10.1016/j.msec.2019.110103
   PubMed Web of Science ®Google Scholar
• Varga N, Hornok V, Janovák L, Dékány I, Csapó E. The effect of synthesis conditions and tunable hydrophilicity on the drug encapsulation capability of PLA and PLGA nanoparticles. Colloids Surf B Biointerfaces. 2019;176:212–218. doi:10.1016/j.colsurfb.2019.01.012
   PubMed Web of Science ®Google Scholar
• Juhász Á, Ungor D, Berta K, Seres L, Csapó E. Spreadsheet-based nonlinear analysis of in vitro release properties of a model drug from colloidal carriers. J Mol Liq. 2021. doi:10.1016/j.molliq.2021.115405
   Web of Science ®Google Scholar
• Chen H, Fu S, Fu L, Yang H, Chen D. Simple synthesis and characterization of hexagonal and ordered al–mcm–41 from natural perlite. Minerals. 2019;9(5):264. doi:10.3390/min9050264
   Web of Science ®Google Scholar
• Huang X, Young NP, Townley HE. Characterization and comparison of mesoporous silica particles for optimized drug delivery. Nanomater Nanotechnol. 2014;4:2. doi:10.5772/58290
   Web of Science ®Google Scholar
• Kruk M, Jaroniec M, Sayari A. Adsorption study of surface and structural properties of MCM-41 materials of different pore sizes. J Phy Chem B. 1997;101:583–589. doi:10.1021/jp962000k
   Web of Science ®Google Scholar
• Xu P, Wang H, Tong R, Du Q, Zhong W. Preparation and morphology of SiO2/PMMA nanohybrids by microemulsion polymerization. Colloid Polym Sci. 2006;284(7):755–762. doi:10.1007/s00396-005-1428-9
   Web of Science ®Google Scholar
• Pandurangappa M, Kumar KS. Micellar mediated trace level mercury quantification through the rhodamine B hydrazide spirolactam ring opening process. Anal Methods. 2011;3(3):715. doi:10.1039/c0ay00693a
   PubMed Web of Science ®Google Scholar
• Kiss T, Katona G, Mérai L, et al. Development of a hydrophobicity-controlled delivery system containing levodopa methyl ester hydrochloride loaded into a mesoporous silica. Pharmaceutics. 2021;13(7):1039. doi:10.3390/pharmaceutics13071039
   PubMed Web of Science ®Google Scholar
• Volpe A, Racioppi M, D’Agostino D, Cappa E, Filianoti A, Bassi PF. Mitomycin C for the treatment of bladder cancer. Minerva Urologica e Nefrologica. 2010;62:133–144.
   PubMed Web of Science ®Google Scholar
• He Q, Shi J, Chen F, Zhu M, Zhang L. An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. Biomaterials. 2010. doi:10.1016/j.biomaterials.2010.01.015
   Web of Science ®Google Scholar
• Wang K, Lu J, Li J, et al. Current trends in smart mesoporous silica-based nanovehicles for photoactivated cancer therapy. J Control Release. 2021;339:445–472. doi:10.1016/j.jconrel.2021.10.005
   PubMed Web of Science ®Google Scholar
• Feng S, Lu J, Wang K, et al. Advances in smart mesoporous carbon nanoplatforms for photothermal–enhanced synergistic cancer therapy. Chem Eng J. 2022. doi:10.1016/j.cej.2022.134886
   PubMed Web of Science ®Google Scholar
• Toth M, Boros IM, Balint E. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci. 2012;103(4):659–669. doi:10.1111/j.1349-7006.2012.02215.x
   PubMed Web of Science ®Google Scholar
• Gopisetty MK, Kovács D, Igaz N, et al. Endoplasmic reticulum stress: major player in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells. J Nanobiotechnology. 2019;17. doi:10.1186/s12951-019-0448-4
   PubMed Web of Science ®Google Scholar
• Lu F, Wu SH, Hung Y, Mou CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small. 2009;5:1408–1413. doi:10.1002/smll.200900005
   PubMed Web of Science ®Google Scholar
• Lu J, Liong M, Sherman S, et al. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnology. 2007;3(2):89–95. doi:10.1007/s12030-008-9003-3
   PubMedGoogle Scholar
• He Q, Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater. 2014;26(3):391–411. doi:10.1002/adma.201303123
   PubMed Web of Science ®Google Scholar